Here is the press release from the NIH and more specific of the information -http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx
Please note there are several strategies in terms of HIV vaccine - not just one approach
. The live vector (adenovirus carrier) is just one approach which failed, but these also failed on the VAX0003 and VAX0004 (Asian study) previously.
Types of Experimental HIV Vaccines:peptide vaccine
: made of tiny pieces of proteins from the HIV virus.recombinant subunit protein vaccine
: made of bigger pieces of proteins that are on the surface of the HIV virus. Examples of a recombinant subunit protein are gp120, gp140, or gp160 produced by genetic engineering.live vector vaccine
: non-HIV viruses engineered to carry genes encoding HIV proteins. The genes are inserted into another vector, which carries them into the body's cells. The genes in turn produce proteins that are normally found on the surface of the HIV virus. This type of vaccine most resembles the HIV virus but is not harmful. Many vaccines used today, like the smallpox vaccine, use this approach.DNA vaccine
: uses copies of a small number of HIV genes which are inserted into pieces of DNA called plasmids. The HIV genes will produce proteins very similar to the ones from real HIV.vaccine combination
: uses any two vaccines, one after another, to create a stronger immune response. Often referred to as "prime-boost strategy."
virus-like particle vaccine (pseudovirion vaccine): a non-infectious HIV look-alike that has one or more, but not all, HIV proteins.
This past semester I had to do a clinical research project. My project involved the HIV vaccine. I believe that the Recombinant approach is the better way to go. The reason being is that the HIV virus has a protein receptor which our immune system also has, it needs this 'anchor' to invade the cell membrane. However, we know already that some individuals in their immune system do not have these receptors -CCR5 or CXCR4. Therefore, if we block the protein synthesis in the immune system through the use of gene therapy the HIV virus can not anchor and replicate. However, CCR5 deficiency only offers some protection since other strains of HIV do not have the CCR5 protein receptor but CXCR4. This is why regional HIV vaccines based on the region will be the better approach. We are closer to understanding the virus and its mechanism, and its not a simple approach.
I know it can be discouraging with the water down media when they do not really present the facts correctly since they are in the business of selling a quick story.
Here is also the link to the HIV vaccine trials network.http://www.hvtn.org/index.html